9 Meters Biopharma, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 43.77 million compared to USD 36.78 million a year ago. Basic loss per share from continuing operations was USD 3.38 compared to USD 3.03 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
2023 | Bidding Procedure Approved for 9 Meters Biopharma, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 14 | |
+76.43% | 5.87B | |
+2.76% | 988M | |
+46.03% | 955M | |
+2.49% | 669M | |
-.--% | 600M | |
-2.15% | 593M | |
+10.28% | 536M | |
-.--% | 500M | |
-2.10% | 470M |
- Stock Market
- Equities
- NMTRQ Stock
- News 9 Meters Biopharma, Inc.
- 9 Meters Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022